Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer.

Turine, Gaetane; Peeters, André; Hermans, Cédric; Eeckhoudt, Stéphane; Duprez, Thierry

doi:10.1007/s13760-017-0751-5

Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer.

Turine, Gaetane

;

Peeters, André

;

Hermans, Cédric

;

Eeckhoudt, Stéphane

;

Duprez, Thierry

(2017) Acta Neurologica Belgica — Vol. 117, n° 3, p. 753-755 (2017)

Files

2017_Turine_Acta_Neurol_Belg.pdf

Restricted Access
Adobe PDF
486.12 KB

Request a copy

Details

Authors

Turine, GaetaneUCLouvain
Author
Peeters, AndréUCLouvain
Author
Hermans, CédricUCLouvain
Author
Eeckhoudt, StéphaneUCLouvain
Author
Duprez, ThierryUCLouvain
Author

Affiliations

UCLouvainSSS/IREC/CARD - Pôle de recherche cardiovasculaire
UCLouvainSSS/IONS/NEUR - Clinical Neuroscience
UCLouvain(SLuc) Service d'hématologie
UCLouvain(SLuc) Service de radiologie
UCLouvain(SLuc) Service de neurologie

Citations

APA
Chicago
FWB

Turine, G., Peeters, A., Hermans, C., Eeckhoudt, S., & Duprez, T. (2017). Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer. Acta Neurologica Belgica, 117(3), 753-755. https://doi.org/10.1007/s13760-017-0751-5 (Original work published 2017)